INKmune References from Scientific Publications

INB16 is the pharmaceutical grade cell line derived from CTV-1 and, although demonstrably different, their effects on resting NK cells are identical

2023

A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic Syndrome
H Arellano-Ballestero, M Sabry, MW Lowdell Cells 12 (4), 633

2022

In Vivo Generation of Memory-like NK Cells for the Treatment of AML and Myelodysplastic Syndrome; Early Clinical Applications of INKmuneTM
KH Orchard, H Ballestero, A Zubiak, C D

2020

Sabry M, Lowdell MW. Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer. Stem Cell Translational Medicine 2020 1-11 DOI: 10.1002/sctm.19-0423

2019

Wagner AK, Alici E, Lowdell MW. Characterization of Human Natural Killer Cells for Therapeutic Use
Cytotherapy. 2019 Mar;21(3):315-326. doi: 10.1016/j.jcyt.2018.11.001. Epub 2019 Mar 23.

Sabry M, Zubiak A, Hood SP, Simmonds P, Arellano-Ballestero H, Cournoyer E, Mashar M, Pockley AG, Lowdell MW. Tumor- and cytokine-primed human natural killer cells exhibit distinct phenotypic and transcriptional signatures. PLoS One. 2019 Jun 26;14(6):e0218674. doi: 10.1371/journal.pone.0218674

Tsirogianni M, Grigoriou E, Kapsimalli V, Dagla K, Stamouli M, Gkirkas K, Konsta E, Karagiannidou A, Gkodopoulos K, Stavroulaki G, Pappa V, Angelopoulou M, Lowdell M, Tsirigotis P. Natural killer cell cytotoxicity is a predictor of outcome for patients with high risk myelodysplastic syndrome and oligoblastic acute myeloid leukemia treated with azacytidine. Leuk Lymphoma. 2019 Apr 5:1-7. doi: 10.1080/10428194.2019.1581935. [Epub ahead of print]

2018

Fehniger TA, Miller JS, Stuart RK, Cooley S, Salhotra A, Curtsinger J, Westervelt P, DiPersio JF, Hillman TM, Silver N, Szarek M, Gorelik L, Lowdell MW, Rowinsky E. A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia. Biology Blood Marrow Transplant 2018:e-pub doi: 10.1016/j.bbmt.2018.03.019

Doherty E & Rouce RH. Primed to kill: CTV-1 stimulated haploidentical NK cells for consolidation of AML.
Biology Blood Marrow Transplant 2018:e-pub; https://doi.org/10.1016/j.bbmt.2018.06.019

2017

Natural killer cells differentiated in vitro from cord blood CD34+ cells are more advantageous for use as an immunotherapy than peripheral blood and cord blood natural killer cells.
Domogala A, Blundell M, Thrasher A, Lowdell MW, Madrigal JA, Saudemont A. Cytotherapy. 2017 Jun;19(6):710-720. doi: 10.1016/j.jcyt.2017.03.068. Epub 2017 Apr 17.

2016

Koehl U, Kalberer C, Spanholtz J, Lee DA, Miller J, Cooley S, Lowdell M, Uharek L, Klingemann H, Curti A, Leung W, Alici E (2016) Advances in clinical NK cell studies, donor selection, manufacturing and quality control. Oncoimmunology; 5(4) e-pub

2015

Kottaridis PD, North, Tsirogianni M, Marden C, Samuel ER, Jide-Banwo S, Grace S, Lowdell MW. Two-stage priming of allogeneic Natural Killer cells for the treatment of patients with acute myeloid leukemia; a phase I trial. PLoS One; Jun 10;10(6):e0123416. doi: 10.1371

2013

Sabry M, Lowdell MW. Tumour-primed NK cells; waiting for the green light. Frontiers in Immunology; 2013: 4:1-7. doi: 10.3389/fimmu.2013

2011

Sabry M, Tsirogianni M, Bakhsh IA, North J, Sivakumaran J, Giannopoulos K, Anderson R, Mackinnon S and Lowdell MW. Leukemic priming of resting NK cells is KIR independent but requires CD15-mediated CD2 ligation and natural cytotoxicity receptors. J.Immunology; 187:6227-6234. doi: 10.4049/jimmunol.1101640

Katodritou E, North J, Kottaridis P, Verrou E, Gastari V, Chadjiaggelidou C, Sivakumaran J, Jide-Banwo S, Tsirogianni M, Zervas K, Lowdell MW. Tumor-primed Natural Killer Cells from Patients with Multiple Myeloma Lyse Autologous, NK-resistant, Bone Marrow-derived Malignant Plasma Cells. Am J Hematology; 86:967-973. doi: 10.1002/ajh.22163.

2007

North J, Bakhsh I, Marden C, Pittman H, Addison E, Navarrete C, Anderson R, Lowdell MW. Tumor-primed human natural killer cells lyse NK-resistant tumor targets: evidence for a two-stage process in resting NK cell activation. Journal of Immunology; 178:85-94. PMID: 17182543

INKmune bibliography